The review team performed a systematic search of PubMed, the Cochrane Library, and Scopus for clinical trials published between January 2004 and July 2023. Two independent reviewers screened titles and abstracts against predefined PICOS criteria and followed PRISMA procedures for study selection. The initial search identified 383 records. After screening, 42 articles underwent full-text review; 38 were excluded for not meeting inclusion criteria, leaving four randomized controlled trials for qualitative synthesis. The authors limited inclusion to RCTs that evaluated an intratympanic steroid regimen administered to patients receiving cisplatin chemotherapy.
All four included studies were randomized controlled trials, but the review team found consistent methodological concerns. Allocation concealment was judged high-risk in every trial. Three of the four RCTs carried a substantial risk of detection bias, as noted by the reviewers. The systematic review therefore flagged internal validity problems that reduce confidence in observed effects. The authors reported these RoB findings explicitly and used them when weighing the overall evidence.
The investigators applied the GRADE framework to rate the quality of evidence from the included RCTs. One trial achieved a high GRADE rating, two trials were rated moderate, and one trial was rated low. These variable ratings reflect the combined influence of study design limitations, potential bias, and inconsistencies in outcomes across trials. The review team emphasized that even the single high-rated study did not, on its own, produce a consistent signal strong enough to establish a protective effect across the body of evidence.
Across the four RCTs, the results did not coalesce into a clear otoprotective benefit for intratympanic steroids against cisplatin-induced hearing loss. The authors concluded that the available randomized evidence is inconsistent: some trials reported favorable outcomes, others reported no significant prevention of hearing decline, and none provided uniformly high-quality proof of clinical benefit. The review did not report pooled quantitative effect estimates because trial heterogeneity precluded a reliable meta-analysis. Where trials differed in reported endpoints, the review team noted that differences in outcome measurements and timing complicated direct comparison of efficacy signals.
The review identified several likely contributors to conflicting results. Differences in steroid selection, delivered concentration, and dosing regimens were present across the trials; the source did not report standardized dosing or timing parameters that would allow harmonized comparison. Timing of intratympanic administration relative to cisplatin exposure varied across studies, and patient populations were not uniform. Those methodological variations—dose, concentration, timing, and participant characteristics—were cited as probable drivers of inconsistent outcomes. The authors stated that these design differences limit the ability to draw definitive conclusions from the current RCT literature.
Based on the reviewed RCTs, the authors did not confirm a consistent protective effect of intratympanic steroid administration for prevention of cisplatin ototoxicity. They concluded that current randomized evidence fails to establish a definitive therapeutic advantage for this approach. The review recommended further randomized trials that employ rigorous, standardized protocols — specifically harmonized steroid regimens, clearly defined timing relative to chemotherapy, uniform outcome measures for hearing, and robust allocation concealment and blinding to reduce detection bias. The source did not provide specific dosing regimens or protocol templates; those details remain to be defined by future investigators.
Limitations documented by the review include the small number of eligible RCTs, consistent high-risk allocation concealment across trials, and variable detection bias in most studies. These constraints reduce certainty about whether intratympanic steroid treatment can prevent cisplatin-induced hearing loss in routine clinical practice. The review closes with a concrete call for rigorously designed RCTs with standardized protocols to resolve remaining clinical questions and to determine whether a reproducible otoprotective effect exists for intratympanic steroid therapy in patients receiving cisplatin chemotherapy.